Lorna Ewart is Emulate’s Executive Vice President in Europe. She brings over 20 years’ experience in the pharmaceutical industry, spanning Bioscience and Drug Safety. In her role at Emulate, Ewart is a member of the Executive Leadership Team and provides oversight for the corporate vision, goals and, science with academics, industry, and regulatory partners. Prior to joining Emulate, Ewart created Veroli Consulting Limited. Here, she served as an independent scientific consultant directing academics, start-up biotechnology companies, and pharmaceutical companies working with Organ-Chips and organoids. Within the pharmaceutical industry, Ewart rapidly developed a reputation as a valued partner with academic institutions, regulatory bodies, and technology developers and most recently successfully established the Microphysiological Systems Centre of Excellence within AstraZeneca’s R&D Biopharmaceuticals Unit in Cambridge, UK. This positioned AstraZeneca at the leading edge of industrial adoption of Organs-on-Chips technology. Earlier in her career, Ewart was the therapy area lead toxicologist for Respiratory and Inflammation in AstraZeneca’s Gothenburg R&D site, Sweden. Following her Ph.D., she joined the Respiratory and Inflammation research area within AstraZeneca, optimizing efficacy in small molecules before moving into preclinical Drug Safety where she led a Safety Pharmacology team delivering GLP data across multiple therapeutic areas. Ewart is a classically trained pharmacologist and obtained her honors degree at the University of Aberdeen and her Ph.D. at the William Harvey Research Institute in London. She has authored over 35 publications and is a fellow of the Royal Society of Biology and British Pharmacological Society.